GLAND

** Gland Pharma GLAD.NS rises 2.4% to 1,622.85 rupees

** Global investor Vanguard's two funds buy ~1.9 mln shares, aggregating to 1.13% stake in the drug maker at 1,588.69 rupees, NSE data shows

** GLAD top gainer on pharma index .NIPHARM, which is trading flat

** Stock down 9% YTD vs NIPHARM's 7.7% decline

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Indian equities set for inflows of up to $1.4 billion on Friday as FTSE March semi-annual rebalancing to come into effect, per analysts

** ICICI Bank ICBK.NS will be the biggest beneficiary, to see inflows worth $426.9 million from weight increases by FTSE, MSCI and BSE, says IIFL

** Large inflows in ICBK due to merger between bank and ICICI Securities ICCI.NS, whose shares will trade for the last time on Friday

** ICCI shareholders to get 67 ICBK shares per 100 shares of ICCI

** Kotak Mahindra Bank KTKM.NS to see $146 million inflows as FTSE increases weight, says Nuvama

** FTSE adds 360 ONE WAM ONEW.NS, Bajaj Housing Finance BAJO.NS, BSE BSEL.NS and other stocks to FTSE All World Index

** Stocks that might see inflows due to FTSE rebalancing include Zomato ZOMT.NS, ITC Hotels ITCT.NS, Gland Pharma GLAD.NS and BAJO

(Reporting by Vivek Kumar M)

(([email protected];))

Feb 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - CONCLUSION OF US FDA INSPECTION AT COMPANY’S JNPC FACILITY, VISAKHAPATNAM

• GLAND PHARMA - INSPECTION WAS CONCLUDED WITH THREE FORM 483 OBSERVATIONS

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

** Shares of Gland Pharma GLAD.NS fall ~3.3% to 1462.8 rupees

** Co's Q3 revenue falls 10.4% on production setbacks at French unit Cenexi's site near Paris

** Cenexi sales down due to regulatory inspections, breakeven now pushed back by a year vs Q3 target

** Jefferies says Cenexi "continued to bleed" and India and US saw the biggest sales disappointment in Q3

** InCred Equities cuts to 'sell' from 'hold' on "repeated delays in Cenexi's turnaround"

** Citi retains 'sell' on GLAD's inablity to optimize its 'world class' injectables manufacturing set-up

** 10 analysts avg rating is 'hold', avg PT is 1671 rupees, implying ~13.5% upside to current price -LSEG data

** Including session's decline, stock down 27% in last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Feb 3 (Reuters) - Gland Pharma Ltd GLAD.NS:

• Q3 CONSOL NET PROFIT 2.05 BILLION RUPEES; IBES EST. 2.04 BILLION RUPEES

• Q3 CONSOL REVENUE FROM OPERATIONS 13.84 BILLION RUPEES; IBES EST. 15.69 BILLION RUPEES

Further company coverage: GLAD.NS

(([email protected];))

Jan 16 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVED ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR DUNDIGAL FACILITY

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];;))

Jan 15 (Reuters) - Gland Pharma Ltd GLAD.NS:

• SHYAMAKANT GIRI WILL ASSUME THE OFFICE OF CHIEF EXECUTIVE OFFICER

Further company coverage: GLAD.NS

(([email protected];;))

Dec 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA - ANSM INSPECTION AT CENEXI'S FONTENAY MANUFACTURING FACILITY

• GLAND PHARMA LTD - CENEXI'S FONTENAY FACILITY RECEIVES 10 OBSERVATIONS FROM ANSM

Source text: ID:nBSEbCwXW2

Further company coverage: GLAD.NS

(([email protected];))

** Shares of generic injectables maker Gland Pharma GLAD.NS rise 2% to 1,810 rupees in early trade

** Stock among top gainers on Nifty Pharma index .NIPHARM which is up 0.19%

** Co gets approval from U.S. FDA for phytonadione injectable emulsion, which is used to treat coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity

** Co expects to launch the drug in the near future

** Avg rating on stock is a "hold," among 10 stocks on pharma index with this rating; median PT is 1,800 rupees - LSEG data

** Day's gains erase weekly loss, stock now up 2% this week

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected]))

Dec 3 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIPT OF US FDA APPROVAL FOR LATANOPROST OPHTHALMIC SOLUTION, 0.005%

• EXPECTS TO LAUNCH THIS PRODUCT THROUGH ITS MARKETING PARTNERS IN FY25

Source text: ID:nNSE85dvSv

Further company coverage: GLAD.NS

(([email protected];;))

** Gland Pharma Ltd GLAD.NS shares jump nearly 10% to 1,770 rupees, set for their best day since August 2023

** Kotak Institutional Equities upgrades drugmaker's stock to "reduce" from "sell"; stock saw a 24% slump over the last three months

** Brokerage says GLAD's Q2 earnings show slump has likely bottomed out, sees sales growth for core business and French unit Cenexi recovering gradually

** Kotak's PT of 1,625 rupees is second-highest among analysts tracking stock - LSEG data

** Investec, Motilal Oswal retain "buy"; Motilal sees earnings growing 20% CAGR between FY25-27 after two years of decline

** Around 2.7 mln shares traded, 11x stock's 30-day avg volume

** Analysts tracking GLAD rate it "hold" on avg - LSEG data

** Stock trims YTD losses to 5.7% but trails Nifty Pharma Index's .NIPHARM 34% jump YTD

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Nov 4 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA Q2 CONSOL NET PROFIT 1.64 BILLION RUPEES; IBES EST. 1.6 BILLION RUPEES

• GLAND PHARMA Q2 CONSOL REVENUE FROM OPERATIONS 14.06 BILLION RUPEES; IBES EST. 14.2 BILLION RUPEES

Source text: [ID:]

Further company coverage: GLAD.NS

(([email protected];;))

Oct 18 (Reuters) - Gland Pharma Ltd GLAD.NS:

• NAMES SHYAMAKANT GIRI AS CEO

Source text for Eikon: ID:nBSE7vHkpc

Further company coverage: GLAD.NS

(([email protected];;))

** Shares of Gland Pharma GLAD.NS tumble as much as 9%, before pulling back to a 4% drop

** Injectables manufacturer posted a surprise drop in Q1 profit

** Ambit Capital says in the acquired Cenexi business, growth and margin trajectory was better than its core business, but recovery to be gradual

** Says increasing rev share from lower-margin, non-US markets, slow-margin recovery in Cenexi to continue capping margins

** Analysts avg rating on GLAD is equivalent of "hold" and median PT is 1,913.5 rupees -LSEG data

** Stock is only loser on the Nifty pharma index on the day, which is up 1.3%

** GLAD cuts YTD gains to 5%, while the pharma index has gained about 11.5%

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Aug 6 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA Q1 CONSOL NET PROFIT 1.44 BILLION RUPEES; IBES PROFIT EST. 2.09 BILLION RUPEES

• GLAND PHARMA Q1 CONSOL REVENUE FROM OPERATIONS 14.02 BILLION RUPEES; IBES EST. 14.95 BILLION RUPEES

Source text for Eikon: ID:nBSE2GZXf7

Further company coverage: GLAD.NS

(([email protected];))

July 25 (Reuters) - Gland Pharma Ltd GLAD.NS:

• CONCLUSION OF US FDA SURPRISE INSPECTION AT DUNDIGAL FACILITY, HYDERABAD

• INSPECTION CONCLUDED WITH TWO 483 OBSERVATIONS

• OBSERVATIONS ARE PROCEDURAL IN NATURE

Source text for Eikon: ID:nNSE6jkd57

Further company coverage: GLAD.NS

(([email protected];;))

July 23 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GETS TENTATIVE APPROVAL FROM USFDA FOR LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION

• UPON FINAL APPROVAL, CO MAY BE ELIGIBLE FOR 180 DAYS OF GENERIC DRUG EXCLUSIVITY

Source text for Eikon: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

** Shares of generic injectables maker Gland Pharma GLAD.NS fall as much as 3.5% to 1,776 rupees; last down 1.3%

** Fosun Pharma Industrial to pare 5% stake in GLAD through block deals for about $172 mln, according to reports

** Fosun, owned by China's Shanghai Fosun Pharmaceutical Group 600196.SS, will sell shares at a 4.9% discount to last closing price, reports add

** GLAD on track for sixth straight session of losses

** Stock among top losers on Nifty Pharma Index .NIPHARM, which is up 0.2%

** Busiest session for GLAD since May 2023 after the stock beat fourth-qtr rev estimates; trading vols. at about 1.1 mln shares, nearly four times the 30-day avg.

** Twelve analysts, on average, rate stock "hold", with median PT of 1,872.50 rupees - LSEG data

** Stock down ~6% YTD vs. an ~18% rise in Nifty pharma index

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

June 18 (Reuters) -

• FOSUN IS SAID TO PLAN BLOCK DEALS TO PARE 6% STAKE IN GLAND PHARMA - BLOOMBERG NEWS

Source text: [https://tinyurl.com/4dw5kfer]

Further company coverage: 600196.SS

(([email protected];))

June 7 (Reuters) - Gland Pharma Ltd GLAD.NS:

• APPOINTMENT OF SRINIVAS SADU AS CEO

• APPOINTMENT OF SRINIVAS SADU AS EXECUTIVE CHAIRMAN

• TAKEN ON RECORD COMPLETION OF TENURE OF CHAIRMAN YIU KWAN STANLEY LAU

Further company coverage: GLAD.NS

(([email protected];;))

** Shares of Gland Pharma GLAD.NS rise as much as 2.5% before trimming some gains; last up 1.2% at 1,903 rupees

** Generic injectables maker said the U.S. FDA completed inspection at co's Visakhapatnam facility with zero 483 observations

** Stock was down ~1% before the announcement

** GLAD is second-biggest gainer on the Nifty pharma index .NIPHARM - down 0.1%

** Analysts' avg rating on stock is "Hold", in line with rival Dr. Reddy's REDY.NS while Cipla CIPL.NS is rated "Buy" - LSEG

** Median PT on GLAD is 1,872.5 rupees

** Including session's gains, GLAD is up ~20% YTD vs 14% surge in NIPHARM

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of Gland Pharma GLAD.NS up 4.5% at 1,873.8 rupees, on track for best day since April 8

** Co's Q4 rev beat estimates but profit fell short

** Jefferies says GLAD's base business EBITDA margin expansion driven by core U.S. sales growth of 8% QoQ on new launches and favourable pricing

** Brokerage adds, base business margin profile is showing continued improvement but acquisition of Cenexi is taking longer than expected to show results

** Rival Dr Reddy's REDY.NS beat Q4 profit estimates, Cipla CIPL.NS and Sun Pharma SUN.NS both missed rev estimates

** GLAD, REDY rated "hold" on avg; CIPL and SUN rated "buy" - LSEG data

** YTD, GLAD down 1.5%; REDY, CIPL and SUN up between 1.2% and 19%

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

BENGALURU, May 22 (Reuters) - Indian generic injectables maker Gland Pharma GLAD.NS reported fourth-quarter profit below estimates on Wednesday, as soaring employee expenses outweighed strong demand in its core markets.

It reported a consolidated net profit of 1.92 billion rupees ($23 million) for the quarter ended March 31, missing analysts' average estimate of 2.41 billion rupees as per LSEG data.

In the year-ago period, the company had reported a profit of 786.8 million rupees which included a one-time impairment charge of 564.6 million rupees.

Its revenue from operations jumped nearly 96% to 15.37 billion rupees, ahead of analysts' estimates of 15.23 billion rupees, led by an eight-fold jump in Europe sales and an 83% growth in U.S. sales.

These markets together constitute about 75% of the company's total revenue.

The revenue was also boosted by Gland Pharma's acquisition of French pharmaceutical group Cenexi in January 2023. Excluding this income, its revenue rose 50% to 11.74 billion rupees.

Sales in the company's other core markets, such as Canada, Australia and New Zealand, rose 58% to 578 million rupees.

However, this was more than offset by its expenses surging 95% to 12.81 billion rupees, mainly due to a more than three-fold jump in employee-related costs and higher raw material prices.

Its tax expenses also surged more than three-fold to 1.06 billion rupees.

Last week, rival Dr Reddy's reported fourth-quarter results above estimates on strong U.S. demand, while Cipla missed revenue estimates due to weakness in its India consumer segment.

Earlier in the day, Sun Pharma SUN.NS reported fourth-quarter revenue below, and profit above estimates.

Separately, the company also declared a dividend of 20 rupees per share.

($1 = 83.2760 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)

(([email protected]; 8800437922;))

May 7 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA LTD - GLAND PHARMA RECEIVES APPROVAL FOR EDARAVONE INJECTION

• GLAND PHARMA LTD - GLAND PHARMA RECEIVES US FDA APPROVAL FOR EDARAVONE INJECTION

Source text for Eikon: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

Repeats for wider distribution with no changes to text

MUMBAI/BENGALURU, May 6 (Reuters) - Global investment firm KKR KKR.N will buy Indian medical devices maker Healthium Medtech HEAT.NS from UK-based Apax Partners in a deal that three sources with direct knowledge of the matter say is valued at 70 billion rupees ($838.60 million).

Healthium and Apax did not immediately respond to Reuters' requests seeking comment, while KKR declined to comment.

KKR will acquire Healthium through a special purpose vehicle - owned by KKR-managed funds - that will have a controlling interest in Healthium group, including Healthium Medtech, the three companies said in a statement.

The acquisition marks KKR's latest investment in the Indian healthcare sector, with the firm already holding stakes in Indian drugmaker J B Chemicals and Pharmaceuticals JBCH.NS, hospital chain operator Max Healthcare MAXE.NS and generic injectables maker Gland Pharma GLAD.NS.

Private equity firm Apax bought Healthium, which is involved in the manufacturing of products used in surgical, post-surgical, and chronic care procedures, in 2018.

($1 = 83.4725 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru, M. Sriram in Mumbai, Kane Wu in Hong Kong; Editing by Janane Venkatraman )

(([email protected]; 8800437922;))

April 29 (Reuters) - Gland Pharma Ltd GLAD.NS:

• RECEIVES APPROVAL FROM US FDA FOR CETRORELIX ACETATE FOR INJECTION

• CO EXPECTS TO LAUNCH THE PRODUCT IN NEAR-TERM THROUGH ITS MARKETING PARTNER

Source text for Eikon: [ID:]

Further company coverage: GLAD.NS

(([email protected];))

** Gland Pharma GLAD.NS fall 6.7% to 1,735.05 rupees; top loser on Nifty pharma index .NIPHARM which is up 0.2%

** Over 9.7 mln shares change hands in 15 block deals as of 9:33 a.m. IST in price range of 1,743.95-1,761.30 rupees/shr - LSEG

** Local media reports say Nicomac Machinery, RP Advisory Services likely to sell 4.4% stake in co via block deal

** More than 11.4 mln shares trade in most active session since early Aug - LSEG

** Stock last down 5.2%, on track for worst day since late-May 2023

** Stock among ten stocks in 20-member pharma index with avg rating of 'buy'; GLAD's median PT is 1,770 rupees - LSEG

** Stock declined 8.4% YTD, compared to pharma index's 14.3% climb

(Reporting by Rama Venkat in Bengaluru)

(([email protected]; https://twitter.com/ramavenkat0607;))

** Shares of Gland Pharma GLAD.NS rise as much as 6.3% to 1,865 rupees, marking sharpest intraday pct gain since Feb. 6

** GLAD eyes busiest day in 16 sessions

** GLAD received U.S. FDA approval on Saturday for Eribulin Mesylate Injection, a cancer treatment drug

** Analysts' average rating on the stock is "buy"; median PT is 1,770 rupees, a discount of ~5.1% to the day's high - LSEG data

** GLAD top gainer on Nifty Pharma index .NIPHARM

** As of last close, stock down ~8.8% YTD vs a 13.8% climb in the pharma index YTD

(Reporting by Anisha Ajith in Bengaluru)

(([email protected]))

** Shares of Gland Pharma GLAD.NS up 2.6% at 1,745.20 rupees; among the top gainers on the Nifty Pharma index .NIPHARM

** Motilal Oswal reiterates "buy" with a TP of 2,240 rupees; cites plans to expand in the rest of the world (ROW) by entering new markets

** Brokerage says revival in sales in core markets such as the U.S., EU, Canada, and Australia, led by new product launches and the re-launch of certain products

** This expansion could result in ROW sales reaching 6.9 bln rupees at 11% CAGR over FY24-26

** Brokerage expects a 13% CAGR in India sales in this period

** Avg rating of 15 analysts close to equivalent of "buy", median PT is 1,913.50 rupees - LSEG data

($1 = 83.1000 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Feb 14 (Reuters) - Gland Pharma Ltd GLAD.NS:

• GLAND PHARMA DEC-QUARTER CONSOL NET PROFIT 1.92 BILLION RUPEES VERSUS 2.32 BILLION RUPEES

• GLAND PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 15.45 BILLION RUPEES VERSUS 9.38 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: GLAD.NS

(([email protected];))